Roche's Tecentriq/Avastin combo wins US approval

3rd June 2020 Uncategorised 0

Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen cleared to treat unresectable or metastatic liver cancer

More: Roche's Tecentriq/Avastin combo wins US approval
Source: News